Login to Your Account

More Phase III Trials Ongoing

Regeneron’s Sarilumab Shines in RA; ‘Competitive’ to Actemra

By Randy Osborne
Staff Writer

Friday, November 22, 2013
Wall Street fell short of rejoicing when Regeneron Pharmaceuticals Inc. popped the lid off Phase III data with sarilumab that met all endpoints in rheumatoid arthritis (RA), and the firm’s chief scientific officer, George Yancopoulos, said he knows why.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription